ABSTRACT
Introduction several cases of Guillain-Barre Syndrome (GBS) associated with SARS-CoV-2 infection have been described. This study illustrated the demographic, clinical, and neurophysiological characteristics of patients with GBS and COVID-19, as well as associated factors with disability at discharge.
Methods A retrospective analytical observational study was conducted. It included patients diagnosed with GBS admitted in a national reference center in Peru between 2019 and 2021. Epidemiological, clinical, neurophysiological and cerebrospinal fluid data were analyzed. A multivariate analysis, using the generalized linear model, was performed, considering the presence of disability at discharge as the dependent variable.
Results 81 subjects diagnosed with GBS were included. The mean age was 46.8 years (SD: 15.2), with a predominance of males (61.73%). The most frequent clinical presentation was the classic sensory-motor form in 74 cases (91.36%) with AIDP (82.35%) as the most frequent neurophysiological pattern in the group with COVID-19, while AMAN pattern predominated (59.26%) in those without COVID-19 (p=<0.000). The disability prevalence ratio at discharge between subjects with COVID-19 and those without COVID-19 was 1.89 (CI 1.06–3.34), p=0.030, adjusted for age, sex, and neurophysiological subtype.
Conclusions The neurophysiologic subtype AIDP, and a higher disability were associated with the presence of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Institute of Neurological Science Ethics committee, approval N 015-2022-CIEI-INCN
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research has not received any specific support from public sector agencies, commercial sector, or non-profit entities.
Conflict of interest: The authors received no support from any organization for the submitted work. The authors have no conflicting interests to declare that are relevant to the content of this article.
E-mail: sofia.sanchez{at}upch.pe, E-mail: aransb21{at}uw.edu, E-mail: jhonhtc122{at}gmail.com, E-mail: darwin1854{at}hotmail.com
Postal address: Av. Honorio Delgado 430. San Martín de Porres, Lima, Perú., Phone: +51933092464
Panamericana Sur 19, Villa EL Salvador 15067, Phone: +51941925104
Postal address: 3980 15th Avenue NE Seattle WA 98105., Phone: +12068597236
Postal address: Jirón Ancash1271, Lima, Perú., Phone: +51 946 873 325
Postal address: Jirón Ancash1271, Lima, Perú., Phone: +51981890390
Data Availability
All data produced in the present study are available upon reasonable request to the authors
